“Comforting and Encouraging” Study Shows JAK Inhibitors Not Linked to Short-Term Heart Woes in Derm Patients
By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology1, the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. A meta-analysis of 45 randomized clinical trials comprised of 12,996 patients disclosed neither an increased risk of major cardiovascular events (MACE) such as […]